Who Paid My Doc
A Phase Iiib, Multi-Center, Non-Randomized, Parallel-Group, Open-Label
Research payments
$1,095,190
Through program year 2024, $1,095,190 in research payments was reported against A Phase Iiib, Multi-Center, Non-Randomized, Parallel-Group, Open-Label, across 252 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $903,159 | 213 |
| 2023 | Research | $192,031 | 39 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Franco Felizarta Bakersfield, CA Named on 26 payments
- Mitchell Whitehead Pensacola, FL Named on 21 payments
- Zachary Henry Fort Lauderdale, FL Named on 18 payments
- Cheryl McDonald Fort Worth, TX Named on 17 payments
- Mezgebe Berhe Dallas, TX Named on 15 payments
- Marc Johnson Charlotte, NC Named on 13 payments
- Margaret Hoffman Terry Allentown, PA Named on 11 payments
- Sonya Heath Birmingham, AL Named on 10 payments
- Sara Bares Omaha, NE Named on 9 payments
- Moti Ramgopal Port Saint Lucie, FL Named on 9 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.